Introduction Diffuse midline glioma (DMG) H3 K27-altered is a type of high-grade gliomas
first recognized as a new entity in the 2016 World Health Organization Classification of …

Background A comprehensive review and description of the clinical features that impact
prognosis for patients with diffuse hemispheric glioma, H3 G34-mutant (G34-DHG) is …

This study aims to elucidate the clinical and molecular characteristics, treatment outcomes
and prognostic factors of patients with histone H3 K27-mutant diffuse midline glioma. We …

Abstract H3 K27M-mutant diffuse midline glioma (H3 K27M-mt DMG) is a rare, highly
invasive tumor with a poor prognosis. The prognostic factors of H3 K27M-mt DMG have not …

Introduction Diffuse midline gliomas (DMG) and diffuse hemispheric glioma (DHG) are both
rare tumors characterized and recognized for specific alterations of histone 3 including …

Diffuse midline glioma H3 K27M-altered is a recently renamed high-grade glioma in the
2021 World Health Organization (WHO) Classification of Central Nervous System Tumors …

Despite recent advances in the understanding of brain tumor pathophysiology, challenges
associated with tumor location and characteristics have prevented significant improvement …

Abstract Purpose Adult Diffuse midline glioma (DMG) is a very rare disease. DMGs are
currently treated with radiotherapy and chemotherapy even if only a few retrospective …

Pediatric high grade gliomas have undergone remarkable changes in recent time with
discovery of new molecular pathways. They have been added separately in current WHO …

Diffuse midline glioma (DMG) is one of fatal glioblastoma multiforme (GBM) with no proven
medical therapies. Tumor treating fields (TTFields) is a new revolutionary therapy for GBM …